HC Wainwright Reiterates “Buy” Rating for enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 112.20% from the stock’s current price.

Several other research firms have also weighed in on ENGN. Weiss Ratings reissued a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. Morgan Stanley lowered enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research note on Thursday, June 18th. UBS Group lowered their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $11.05.

enGene Price Performance

Shares of ENGN traded up $0.07 during mid-day trading on Tuesday, reaching $1.89. The company had a trading volume of 694,833 shares, compared to its average volume of 1,005,779. enGene has a 1-year low of $1.40 and a 1-year high of $12.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. The company has a market capitalization of $126.28 million, a price-to-earnings ratio of -0.87 and a beta of -0.28. The company’s 50 day simple moving average is $1.82 and its 200 day simple moving average is $4.11.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.47). Analysts expect that enGene will post -1.84 EPS for the current year.

Institutional Investors Weigh In On enGene

A number of large investors have recently added to or reduced their stakes in ENGN. Cresset Asset Management LLC purchased a new position in shares of enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co bought a new stake in shares of enGene during the 2nd quarter valued at $38,000. Raymond James Financial Inc. increased its stake in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Jump Financial LLC bought a new stake in enGene during the fourth quarter worth about $121,000. Finally, Millennium Management LLC lifted its holdings in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.